ArticlePediatric blood & cancer2026
Prevalence and Trajectory of Household Material Hardship Among Children With Advanced Cancer.
Article in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND/
objectivesFamilies of children with advanced cancer living in poverty experience inferior outcomes including poor parent mental health and worse child quality of life. Household material hardship (HMH: food, housing, transportation, and/or utility insecurity) is a modifiable poverty exposure-and potential intervention target-that has not been systematically evaluated in pediatric advanced cancer. We aimed to determine the feasibility of systematic HMH evaluation among families of children with advanced cancer and to describe the prevalence and trajectory of HMH at baseline advanced cancer determination and at 12-week follow-up.
methodsParents of children < 18 years with new advanced cancer (defined as new palliative care consult, new relapse/progression, initial diagnosis of poor prognosis cancer, or early phase trial enrollment) receiving oncology care at two large pediatric cancer centers in Boston, MA, or Dallas, TX, were offered an opportunity to consent. Enrolled participants completed questionnaires at baseline and 12-week follow-up. Feasibility was defined as ≥ 75% consent rate and ≥ 75% complete baseline HMH data.
resultsOf 90 parents approached, 80 (89%) consented to participation and 79 (99%) provided complete baseline HMH data. Nearly all participants approached for the 12-week follow-up survey completed it (n = 65/66; 98%) with 100% complete HMH data. At baseline, 42% of households reported HMH and at 12 weeks, 40% of households reported HMH.
conclusionSystematic longitudinal HMH evaluation is feasible in pediatric advanced cancer. HMH remains highly prevalent over time, with approximately 40% of families reporting HMH at baseline and 12-week follow-up. Interventions to address HMH are essential to mitigate outcome disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.